Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Erectile dysfunction can have psychological consequences as it can be tied to relationship difficulties and self-image.
The classification of Erectile Dysfunction Drugs includes Sildenafil, Tadalafil and others, and the proportion of Sildenafil in 2018 is about 99.85%, and the proportion is in decreasing trend from 2014 to 2018.Erectile Dysfunction Drugs is widely used through Hospital Pharmacies, Private Clinics, Retail Pharmacies, E-Commerce (B2B) and E-Commerce (B2C). The most proportion of Erectile Dysfunction Drugs is used for Hospital Pharmacies, and the sales proportion in 2018 is 29.24%.North America is the largest consumption place, with a consumption market share nearly 39.05% in 2018. Following North America, Europe is the second largest consumption place with the consumption market share of 30.52%. Despite of increasing demand for erectile dysfunction drugs, this market is going to experience a decline in forecast period due to patent expiration of major brands. On the contrary, it will provide the key opportunity for generic manufacturers to enter the market. Generic drugs are the promising opportunity for this market.

Market Analysis and Insights: Global Erectile Dysfunction Drugs Market
The global Erectile Dysfunction Drugs market is valued at US$ 5375.7 million in 2019. The market size will reach US$ 8119.6 million by the end of 2026, growing at a CAGR of 6.0% during 2021-2026.

Global Erectile Dysfunction Drugs Scope and Market Size
Erectile Dysfunction Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Erectile Dysfunction Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Sildenafil
Tadalafil
Others
In 2018, Sildenafil accounted for a major share of 56% in the global Erectile Dysfunction Drugs market. And this product segment is poised to reach 3366.84 M USD by 2025 from 2483.77 M USD in 2019.

Segment by Application
Hospital Pharmacies
Private Clinics
Retail Pharmacies
E-Commerce (B2B)
E-Commerce (B2C)
In Erectile Dysfunction Drugs market, Hospital Pharmacies segment holds an important share in terms of application, and it is expected to reach a volume of 458.57 (M Pill) by 2025, at a CAGR of 12.63% during 2018 and 2025. It means that Erectile Dysfunction Drugs will be promising in the Hospital Pharmacies field in the next couple of years.

By Company
Eli Lilly
Pfizer
Bayer
BaiYunShan General Factory
S.K. Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
CSBIO.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia